logo conference-reports


Educational funding by logo MSD_HIV

HIV-Glasgow 2018 – Fostemsavir (BRIGHTE phase 3 study): 48-week subgroup analysis

Dr Peter Ackerman presented the recent results of the BRIGHTE study – an analysis of the prodrug fostemsavir as an attachment inhibitor against HIV. Metabolism to the active moiety temsavir is via the gastrointestinal tract and it has been designed specifically for HIV-1 infected heavily treatment-experienced patients (HTP) who are failing their current therapy. In the BRIGHTE study, 86% of patients coming into the trial had a prior history of AIDS.
Tjenesten du prøver å få tilgang til er bare tilgjengelig for registrerte brukere. For å fortsette vennligst logg inn eller registrer deg for en gratis konto på Univadis